Psychotropic drug prescribing in an Australian specialist child and adolescent eating disorder service: a retrospective study

Journal of Eating Disorders

Thinh Nguyen³  Julie McCormack²  Emily Harper²  Hunna J Watson⁴  Julia K Moore¹ 

[1] The School of Paediatrics and Child Health, University of Western Australia, Perth, Australia;Princess Margaret Hospital for Children, Perth, Australia;The School of Psychiatry and Clinical Neurosciences, University of Western Australia, Perth, Australia;The School of Psychology and Speech Pathology, Curtin University, Perth, Australia

关键词: Pharmacology;    Eating disorders;    Drug therapy;    Child;    Binge eating;    Adverse effects;    Adolescent;   

Others  :  802630
DOI  :  10.1186/2050-2974-1-27

 received in 2013-01-12, accepted in 2013-05-31,  发布年份 2013

【 摘 要 】

Background

To describe the rates, indications, and adverse effects of psychotropic drug prescription in a specialist tertiary hospital child and adolescent eating disorder service.

Methods

Retrospective case note study of all active eating disorder patients (N = 115) over the period of treatment from referral to time of study (M = 2 years), covering patient demographics, clinical characteristics, drug prescriptions, indications, and adverse effects.

Results

Psychotropic drugs were prescribed in 45% of cases, most commonly antidepressants (41%), followed by anxiolytics (29%) and antipsychotics (22%), with 8% initiated before referral to the specialist eating disorder program. Common indications were depressed mood, agitation, anxiety, and insomnia. Patient clinical severity and complexity was associated with prescribing. Adverse effects, mostly minor, were recorded in 23% of antidepressant prescriptions, 39% of antipsychotic prescriptions, and 13% of anxiolytic prescriptions. Second generation antipsychotic prescription was associated with subsequent new onset binge eating, in this preliminary observational study. Self-harm by overdose of psychotropics occurred in 11% of patients prescribed medication.

Conclusions

Psychotropic medications were frequently prescribed to adolescent eating disorder patients to treat distressing symptoms. Prospective randomised controlled trials to clarify efficacy and safety are needed. Given the difficulties of conducting clinical trials in this population, services are encouraged to monitor and audit medication safety and efficacy in everyday practice, and to report their findings.

【 授权许可】

   
2013 Moore et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Wade T, Bergin J, Tiggemann M, Bulik C, Fairburn CG: Prevalence and long-term course of eating disorders in an adult Australian cohort. Aust N Z J Psychiatry 2006, 40:121-128.
• [2]Treasure J, Claudino AM, Zucker N: Eating disorders. Lancet 2010, 375:583-593.
• [3]Van den Eynde F, Treasure J: Neuroimaging in eating disorders and obesity: implications for research. Child Adolesc Psychiatr Clin N Am 2009, 18:95-115.
• [4]Chui HT, Christensen BK, Zipursky RB, Richards BA, Hanratty MK, Kabani NJ, Mikulis DJ, Katzman DK: Cognitive function and brain structure in females with a history of adolescent-onset anorexia nervosa. Pediatrics 2008, 122:e426-e437.
• [5]Steinhausen H-C: Outcome of eating disorders. Child Adolesc Psychiatr Clin N Am 2009, 18:225-242.
• [6]American Psychiatric Association: Practice guideline for the treatment of patients with eating disorders. 3rd edn. Washington: American Psychiatric Association; 2006.
• [7]Beumont P, Hay P, Beumont D, Birmingham L, Derham H, Jordan A, Kohn M, McDermott B, Marks P, Mitchell J, et al.: Australian and New Zealand clinical practice guidelines for the treatment of anorexia nervosa. Aust N Z J Psychiatry 2004, 38:659-670. [Erratum appears in Aust N Z J Psychiatry. 2004 Nov-Dec;38(11–12):987]
• [8]National Institute for Clinical Excellence: Eating Disorders. NICE clinical guideline: Core Interventions in the Treatment and Management of Anorexia Nervosa, Bulimia Nervosa and Related Eating Disorders; 2004. Available at http://www.nice.org.uk/CG9 webcite
• [9]Aigner M, Treasure J, Kaye W, Kasper S: Disorders WTFoE: World Federation of Societies for Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Eating Disorders. World J Biol Psychiatry 2011, 12:400-443.
• [10]Powers PS, Bruty H: Pharmacotherapy for eating disorders and obesity. Child Adolesc Psychiatr Clin N Am 2009, 18:175-187.
• [11]Correll CU, Kratochvil CJ, March JS: Developments in pediatric psychopharmacology: focus on stimulants, antidepressants, and antipsychotics. J Clin Psychiatry 2011, 72:655-670.
• [12]Holtkamp K, Konrad K, Kaiser N, Ploenes Y, Heussen N, Grzella I, Herpertz-Dahlmann B: A retrospective study of SSRI treatment in adolescent anorexia nervosa: insufficient evidence for efficacy. J Psychiatr Res 2005, 39:303-310.
• [13]Walsh BT, Kaplan AS, Attia E, Olmsted MP, Parides M, Carter JC, Pike KM, Devlin MJ, Woodside B, Roberto CA, Rockert W: Fluoxetine after weight restoration in anorexia nervosa: A randomized controlled trial. JAMA 2006, 295:2605-2612.
• [14]Hammad TA, Laughren T, Racoosin J: Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 2006, 63:332-339.
• [15]Franko DL, Keel PK: Suicidality in eating disorders: occurrence, correlates, and clinical implications. Clin Psychol Rev 2006, 26:769-782.
• [16]Bulik CM, Thornton L, Pinheiro AP, Plotnicov K, Klump KL, Brandt H, Crawford S, Fichter MM, Halmi KA, Johnson C, et al.: Suicide attempts in anorexia nervosa. Psychosom Med 2008, 70:378-383.
• [17]Cantor C, Neulinger K: The epidemiology of suicide and attempted suicide among young Australians. Aust N Z J Psychiatry 2000, 34:370-387.
• [18]Hay PJ, Claudino AM: Clinical psychopharmacology of eating disorders: a research update. Int J Neuropsychopharmacol 2012, 15:209-222.
• [19]Norris ML, Spettigue W, Buchholz A, Henderson KA, Gomez R, Maras D, Gaboury I, Ni A: Olanzapine use for the adjunctive treatment of adolescents with anorexia nervosa. J Child Adolesc Psychopharmacol 2011, 21:213-220.
• [20]Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK: Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009, 302:1765-1773. [Erratum appears in JAMA. 2009 Dec 2;302(21):2322]
• [21]Fazeli PK, Calder GL, Miller KK, Misra M, Lawson E, Meenaghan E, Lee H, Herzog D, Klibanski A: Psychotropic medication use in anorexia nervosa between 1997 and 2009. Int J Eat Disord 2012, 45(8):6-970.
• [22]Cooke RA, Chambers JB, Singh R, Todd GJ, Smeeton NC, Treasure J, Treasure T: QT interval in anorexia nervosa. Br Heart J 1994, 72:69-73.
• [23]Ritchie B, Norris ML: QTc prolongation associated with atypical antipsychotic use in the treatment of adolescent-onset anorexia nervosa. Journal of the Canadian Academy of Child and Adolescent Psychiatry 2009, 18:60-63.
• [24]Nielsen J, Graff C, Kanters JK, Toft E, Taylor D, Meyer JM: Assessing QT interval prolongation and its associated risks with antipsychotics. CNS Drugs 2011, 25:473-490.
• [25]Brewerton TD, Shannon M: Possible clozapine exacerbation of bulimia nervosa. Am J Psychiatry 1992, 149:1408-1409.
• [26]Bromel T, Blum WF, Ziegler A, Schulz E, Bender M, Fleischhaker C, Remschmidt H, Krieg JC, Hebebrand J: Serum leptin levels increase rapidly after initiation of clozapine therapy. Mol Psychiatry 1998, 3:76-80.
• [27]Crockford DN, Fisher G, Barker P: Risperidone, weight gain, and bulimia nervosa. Canadian Journal of Psychiatry - Revue Canadienne de Psychiatrie 1997, 42:326-327.
• [28]Mehler C, Wewetzer C, Schulze U, Warnke A, Theisen F, Dittmann RW: Olanzapine in children and adolescents with chronic anorexia nervosa. A study of five cases. Eur Child Adolesc Psychiatry 2001, 10:151-157.
• [29]Theisen FM, Linden A, Konig IR, Martin M, Remschmidt H, Hebebrand J: Spectrum of binge eating symptomatology in patients treated with clozapine and olanzapine. J Neural Transm 2003, 110:111-121.
• [30]Theisen FM, Cichon S, Linden A, Martin M, Remschmidt H, Hebebrand J: Clozapine and weight gain. Am J Psychiatry 2001, 158:816.
• [31]McKnight RF, Park RJ: Atypical antipsychotics and anorexia nervosa: a review. Eur Eat Disord Rev 2010, 18:10-21.
• [32]Eddy KT, Dorer DJ, Franko DL, Tahilani K, Thompson-Brenner H, Herzog DB: Diagnostic crossover in anorexia nervosa and bulimia nervosa: implications for DSM-V. Am J Psychiatry 2008, 165:245-250.
• [33]Graae F, Milner J, Rizzotto L, Klein RG: Clonazepam in childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry 1994, 33:372-376.
• [34]Watson HJ: Combined psychological and pharmacological treatment of pediatric anxiety disorders. In Handbook of child and adolescent anxiety disorders. Edited by McKay D, Storch EA. New York: Springer Publishing; 2011:379-402.
• [35]Rossi G, Balottin U, Rossi M, Chiappedi M, Fazzi E, Lanzi G: Pharmacological treatment of anorexia nervosa: a retrospective study in preadolescents and adolescents. Clin Pediatr (Phila) 2007, 46:806-811.
• [36]Gowers S, Claxton M, Rowlands L, Inbasagaran A, Wood D, Yi I, Hugo P, Clark-Stone S, Bryant-Waugh R, Nicholls D, Ayton A: Drug prescribing in child and adolescent eating disorder services. Child and Adolescent Mental Health 2010, 15:18-22.
• [37]Australian Bureau of Statistics: Australian demographic statistics, March 2011. ABS, Canberra: cat. no. 3101.0; 2011. http://www.abs.gov.au webcite
• [38]American Psychiatric Association: Diagnostic and statistical manual of mental disorders, 4th edition, text revised. 4th edn. Washington, DC: American Psychiatric Association; 2000.
• [39]Fairburn CG, Cooper Z: The Eating Disorder Examination. In Binge eating: nature, assessment and treatment. 12th edition. Edited by Fairburn CG, Wilson GT. New York: Guilford Press; 1993:317-360.
• [40]Kovacs M: Manual of the Children‘s Depression Inventory. New York: Multi-Health Systems; 1992.
• [41]March JS, Parker JD, Sullivan K, Stallings P, Conners CK: The Multidimensional Anxiety Scale for Children (MASC): factor structure, reliability, and validity. J Am Acad Child Adolesc Psychiatry 1997, 36:554-565.
• [42]Armstrong JG, Putnam FW, Carlson EB, Libero DZ, Smith SR: Development and validation of a measure of adolescent dissociation: The Adolescent Dissociative Experiences Scale. J Nerv Ment Dis 1997, 185:491-497.
• [43]Timbremont B, Braet C, Dreessen L: Assessing depression in youth: Relation between the Children’s Depression Inventory and a structured interview. J Clin Child Adolesc Psychol 2004, 33:149-157.
• [44]Centers for Disease Control and Prevention: Epi Info 7 (Version 7.1.0.6) [Computer Program]. 2012. http://wwwn.cdc.gov/epiinfo/html/downloads.htm webcite
• [45]Clinical growth charts. http://www.cdc.gov/growthcharts/clinical_charts.htm webcite
• [46]Centers for Disease Control and Prevention: Clinical growth charts. Retrieved August 15, 2012. 2010. http://www.cdc.gov/growthcharts/clinical_charts.htm webcite
• [47]Hudson JI, Hiripi E, Pope HG Jr, Kessler RC: The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. Biol Psychiatry 2007, 61:348-358.
• [48]Swanson SA, Crow SJ, Le Grange D, Swendsen J, Merikangas KR: Prevalence and correlates of eating disorders in adolescents. Results from the national comorbidity survey replication adolescent supplement. Arch Gen Psychiatry 2011, 68:714-723.
• [49]Gebhardt S, Haberhausen M, Krieg J-C, Remschmidt H, Heinzel-Gutenbrunner M, Hebebrand J, Thiesen FM: Clozapine/olanzapine-induced recurrence or deterioration of binge eating-related eating disorders. J Neural Transm 2007, 114:1091-1095.
• [50]Keys A, Brozek J, Henschel A, Mickelson O, Taylor HL: The biology of human starvation (2 vols). Minneapolis, Minnesota: University of Minnesota Press; 1950.
• [51]Lambert TJR, Chapman LH: Consensus Working Group: Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement. Med J Aust 2004, 181:544-548.
• [52]Hetrick S, Alvarez-Jimenez M, Parker A, Hughes F, Willet M, Morley K, Fraser R, McGorry PD, Thompson A: Promoting physical health in youth mental health services: ensuring routine monitoring of weight and metabolic indices in a first episode psychosis clinic. Australas 2010, 18:451-455.
• [53]Thompson A, Hetrick SE, Alvarez-Jiménez M, Parker AG, Willet M, Hughes F, Gariup M, Gomez DL, McGorry PD: Targeted intervention to improve monitoring of antipsychotic-induced weight gain and metabolic disturbance in first episode psychosis. Aust N Z J Psychiatry 2011, 45:740-748.
• [54]Hazell L, Shakir SAW: Under-reporting of adverse drug reactions : a systematic review. Drug Saf 2006, 29:385-396.
• [55]Norris ML, Spettigue W, Buchholz A, Henderson KA, Obeid N: Factors influencing research drug trials in adolescents with anorexia nervosa. Eat Disord 2010, 18:210-217.